Eisai Center for Genetics Guided Dementia Discovery to open in spring. Utilizing the insights gained from the AiM Institute, the Center will harness the power of human genetics to develop next-generation medicines for Alzheimer’s disease (AD) and other dementias.
Epochal Precision Anti-Cancer Therapeutics (EPAT) established in Exton, Pa. EPAT focuses on oncology drug development utilizing Eisai’s unique Antibody-Drug Conjugate RESPECT® technology, proprietary payloads, and bispecific antibodies.
Signs strategic collaboration for the worldwide co-development and co-commercialization of cancer agent with Merck & Co., Inc.
Eisai Inc. signed an agreement with Grupo Biotoscana (GBT), granting GBT the exclusive licensing rights to commercialize two oncology and two neurology products throughout most of Latin America. Eisai will continue to retain the rights to the two oncology products in Mexico
Expands existing collaboration agreement with Biogen to develop and commercialize Investigational Alzheimer’s disease treatments
Eisai Andover innovative Medicines (AiM) Institute established to discover biology driven precision medicines
Enter into collaboration with Biogen to develop and commercialize investigational Alzheimer’s disease treatments
Entered into a worldwide collaboration agreement with Purdue Pharma for the clinical development and commercialization of an investigational compound for the treatment of insomnia
Founds H3 Biomedicine to bolster personalized cancer treatment discovery; establishes sales and marketing subsidiaries in Brazil and Mexico
Initiates metabolic franchise; establishes sales and marketing subsidiary in Canada
Acquires MGI Pharma, Inc., including manufacturing facility in Baltimore, Md.
Acquires Morphotek Inc.to bolster monoclonal antibody development
Starts oncology franchise
Eisai Inc. reaches sales of $2 billion
Achieves product sales of $1 billion
|1997||Launches first product (neurology); begins production/packaging operations in US|
|1996||Introduces field sales force|
Eisai Inc. is established as US commercial subsidiary
|1987||Eisai creates R&D presence in Andover, Mass.|
To learn more about Eisai's global milestones, please click here.